Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
0(0%)
Results Posted
57%(8 trials)

Phase Distribution

Ph phase_1
7
50%
Ph phase_2
6
43%
Ph phase_3
1
7%

Phase Distribution

7

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
7(50.0%)
Phase 2Efficacy & side effects
6(42.9%)
Phase 3Large-scale testing
1(7.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

14 of 14 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(14)

Detailed Status

Completed14

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (50.0%)
Phase 26 (42.9%)
Phase 31 (7.1%)

Trials by Status

completed14100%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_1

Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

NCT00859118
completedphase_2

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

NCT00569946
completedphase_2

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

NCT00219557
completedphase_2

Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma

NCT01273662
completedphase_2

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

NCT00389441
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT00859118Phase 1

Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

Completed
NCT00569946Phase 2

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

Completed
NCT00219557Phase 2

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

Completed
NCT01273662Phase 2

Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma

Completed
NCT00389441Phase 2

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Completed
NCT00735904Phase 2

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Completed
NCT00471146Phase 3

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Completed
NCT00094055Phase 2

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Completed
NCT00692341Phase 1

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

Completed
NCT01469052Phase 1

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

Completed
NCT00949624Phase 1

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

Completed
NCT01020136Phase 1

A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers

Completed
NCT00905814Phase 1

A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers

Completed
NCT00918632Phase 1

Food Effect Study Of AG-013736 In Healthy Volunteers

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14